Skip to content

Vitamin D and Zinc Levels in Patients Undergoing Ergometry Test

Vitamin D and Zinc Levels in Patients Undergoing Ergometry Test

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01080274
Enrollment
200
Registered
2010-03-04
Start date
2010-03-31
Completion date
2011-03-31
Last updated
2010-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Keywords

ergometry, vitamin d, zinc

Brief summary

Low vitamin D levels were found to be associated with cardiovascular morbidity and mortality. Low zinc levels are associated with an increased atherosclerotic burden. Therefore we hypothesized that patients with pathological stress test would have low levels of Vitamin D and zinc compared to patients with a normal stress test.

Detailed description

Hypovitaminosis D is generally defined as 25(OH)D levels of \< 20ng/ml, while levels of 21-29ng/ml indicate insufficiency and those above 30ng/ml are regarded as sufficient. The rational behind the observations associating vitamin D deficiency with CVD is that on the one hand, hypovitaminosis D was found to be associated with traditional risk factors such as hypertension (HTN),diabetes mellitus (dm),obesity, dyslipidemia and metabolic syndrome , on the other hand, experimental data demonstrated that vitamin D could affect cardiac muscle cells directly, control parathyroid (PTH) hormone secretion, regulate the rennin- angiotensin- aldosterone system and the immune system, all of which could influence cardiovascular risk. Epidemiological studies further support this association, demonstrating high prevalence of hypovitaminosis D among U.S. adults with cardiovascular disease (74%). An association between low vitamin D levels and increased myocardial infarction risk as well as total mortality has been also observed. Low 25hydroxyvitamin D\[ 25(OH)D\] levels were also independently associated with all cause and CVD mortality among patients scheduled for coronary catheterization.

Interventions

None listed

Sponsors

Assaf-Harofeh Medical Center
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Over 18 years old * CCT \> 60 ml/min * No IHD * No hyper/hypoparathyroidism * No active malignancy * Not taking calcium, phosphate

Exclusion criteria

* Under 18 years of age * Not fulfilling inclusion criteria

Design outcomes

Primary

MeasureTime frame
positive stress testone year

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026